A/Prof David Westerman
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
271 Scholarly works
4 Projects
HIGHLIGHTS
2024
Research grants (ARC, NHMRC, MRFF)
ADAPT (Achieving Durable Remission via Adaptive Pro-Survival Targeting in Acute Myeloid Leukaemia)
2022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752021
Journal article
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
DOI: 10.1182/bloodadvances.20210050832021
Research contracts (non-grants)
Wilson Centre for Lymphoma Genomics
2020
Journal article
BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia
DOI: 10.1182/blood-2020-1377752020
Journal article
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
DOI: 10.1182/BLOOD.20190042052017
Research Contracts
Christine and Bruce Wilson Centre for Lymphoma Genomics
RECENT SCHOLARLY WORKS
2026
Journal article
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
DOI: 10.1182/bloodadvances.20250166462026
Journal article
Flow cytometric assessment of measurable residual disease in acute myeloid leukaemia: a summary of current Australasian practice and future directions
DOI: 10.1111/imj.703362026
Journal article
KRAS internal tandem duplications and alternative driver variants in BRAF Val600Glu negative hairy cell leukemia
DOI: 10.1080/10428194.2026.26150552026
Journal article
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
DOI: 10.1182/blood.20250323072025
Journal article
Landscape of TP53 abnormalities and IGHV mutational profile in untreated Australian patients with chronic lymphocytic leukaemia
DOI: 10.1016/j.pathol.2025.06.0132025
Journal article
Immunophenotypic identification of ETP-like T-ALL using CD1a, CD165 and CD184.
DOI: 10.1182/blood-2025-33692025
Journal article
Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study
DOI: 10.1182/blood-2025-38912025
Journal article
Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA/ELN expert panel
DOI: 10.3324/haematol.2025.288228